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Abstract: 
Background  
     In this study we investigated whether adipose-derived stem cells (ADSCs) had 
any beneficial protective effects on liver injury and regeneration in vivo. Moreover, we 
examined whether ADSCs protect hepatocytes by trophic molecules.  
 Materials and Methods 
     We transplanted ADSCs into mice after 70% hepatectomy (Hx) and 
ischemia-reperfusion (I/R), and observed liver injury and regeneration after reperfusion. 
We co-cultured hepatocytes with ADSCs using a Transwell System for seven days and 
evaluated the viabilities of hepatocytes and the cytokine levels in the culture medium. 
Bevacizumab was used in order to confirm the effect of VEGF on hepatocytes. 
Results 
     ADSCs improved serum liver function at six hours after reperfusion in a 
non-lethal model and stimulated liver regeneration at 24 hours after reperfusion in a 
lethal model. VEGF levels in the culture medium increased by co-culture ADSCs with 
hepatocytes. ADSCs improved the viabilities of hepatocytes. The inhibited production 
of VEGF by bevacizumab did not affect the viability of hepatocytes.  
Conclusions 
     ADSCs were able to ameliorate liver injury and stimulate liver regeneration in 
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subsequent Hx and I/R injured model mice. Furthermore, hepatocytes were protected by 
the trophic molecules of the ADSCs. However, such protective effects might be 
provided by mechanisms other than VEGF signaling.  
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Abbreviations: 
Hepatectomy: Hx 
Ischemia-reperfusion: I/R 
Mesenchymal stem cells: MSCs 
Adipose-derived stem cells: ADSCs 
Vascular endothelial growth factor: VEGF 
Hepatocyte growth factor: HGF 
Tumor necrosis factor-α: TNF-α 
Interleukin: IL 
The ratio of liver weight to body weight: Lw / Bw 
Aspartate aminotransferase: AST  
Alanine aminotransferase: ALT 
Total bilirubin: T-Bil 
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Introduction: 
     During major hepatectomy or liver transplantation, repetitive clamping of the 
hepatoduodenal ligament (the Pringle maneuver) is effective to reduce blood loss.  
However, this procedure places the liver under severe ischemia-reperfusion (IR) stress. 
In addition, the volume of the liver is substantially reduced after a major hepatectomy. 
These procedures additively or synergistically damage postoperative hepatic function 
and increase the incidence of postoperative morbidity and mortality. Although various 
strategies against I/R ［1］ stress or liver volume loss ［2, 3］ have been reported, few 
studies have examined I/R and hepatectomy (Hx) specifically. Then we now have 
focused on “the stem cells therapy”. After transplantation these cells can support a 
host’s liver function and thereby can open the way to further treatment as well as liver 
regeneration. The preeminent candidates as a source of stem cells are mesenchymal 
stem cells (MSCs), which can be obtained from different sources, such as bone marrow 
［4］, umbilical cord blood ［5］, amniotic fluid ［6］, scalp tissue ［7］, placenta ［8］, and 
adipose tissue ［9, 10］ from the human body. MSCs possess both multipotentiality and 
semi-infinite proliferation ability［4 - 10］. Currently, “adipose-derived stem cells” 
(ADSCs) have been isolated [11, 12] and shown to possess the potential to differentiate 
into cells and organs of mesodermal origin as well as nonmesodermal origin. As many 
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as 1% of adipose cells are estimated to be ADSCs, compared with 0.001% – 0.002% of 
those found in bone marrow ［13, 14］. These cells play a role in healing tissue damage, and 
are being investigated in phase I clinical trials for healing recurrent fistula in Crohn’s 
disease ［15］. Therefore, ADSCs have a wide range of clinical applications in many fields 
of surgery ［16］.  
     Recently, the trophic effects related to MSC-secreted bioactive molecules have 
been elucidated ［17］. Moreover, Yarmush et al. ［18］ proposed that the molecules 
produced by MSCs could directly modulate hepatocyte death and regeneration in vitro 
and in vivo. Weil et al. ［19］ reported that MSCs might increase the viability and 
proliferative capacity of fetal intestinal epithelial cells after hypoxic injury via the 
paracrine release of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and 
hepatocyte growth factor (HGF), as well as the down-regulation of apoptotic signaling. 
It has also been reported that trophic factors, especially VEGF, secreted by human 
MSCs, have enhanced islet survival and function after transplantation ［20］. Furthermore, 
several studies of gastric ulcers have suggested that MSCs might accelerate the healing 
of these ulcers by a VEGF-dependent mechanism ［21］. VEGF is a well-known signal 
protein produced by cells that stimulates vasculogenesis and angiogenesis, and the most 
important member is VEGF-A ［22, 23］. However, other functions of VEGF, such as its 
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anti-apoptotic effects have also been reported ［24, 25］. 
     The aim of this study was to examine the beneficial effects of ADSCs on liver 
injury and regeneration after subsequent Hx and I/R in vivo, and to clarify whether 
VEGF was an essential signaling molecule for the hepatocytes-protective effects of 
ADSCs in vitro. 
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Materials and Methods: 
Isolation and culturing of ADSCs 
     STEMPRO® human ADSCs were purchased from Life Technologies™, Tokyo, 
Japan ［26］. The ADSCs were isolated from human adipose tissues collected during 
liposuction procedures and cryopreserved from primary cultures. Before 
cryopreservation, the ADSCs were expanded for one passage in MesenPRO RS® 
medium (Life Technologies).  Cells were tested for purity by flow cytometry and for 
their ability to differentiate into osteogenic, chondrogenic, and adipogenic lineages. 
These cells were positive for CD29, CD44, CD73, CD90, CD105, and CD166 (> 95%), 
and negative for CD14, CD31, CD45, and Lin1 (< 2%). Thawing of the cells and 
initiation of the culture process were performed according to the manufacturer’s 
instructions. ADSCs were plated in tissue culture flasks and cultured with MesenPRO 
RS® basal medium (Life Technologies) containing 2% fetal bovine serum (FBS), 
MesenPRO RS® growth supplement (Life Technologies), 2 mM of L-glutamine at 37°C, 
5% CO2 and 90% humidity. When cells were attached to the growth surface, the 
medium was replaced with an equal volume of fresh complete MesenPRO RS® medium. 
Cells were utilized for experimentation between passages 2 and 5. At the time of 
ADSCs administration, cells were harvested with 0.05% trypsin-EDTA (invitrogen, 
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Tokyo) and washed twice with phosphate buffered saline (PBS). Cells were then 
transplanted in a state of being dissolved in PBS. 
ADSCs transplantation into mice with liver injury  
     We used six-weeks-old female BALB/c nu-nu mice (Charles River™, Tokyo, 
Japan). The mice were divided into two groups: 70% hepatectomy (Hx) following 
ischemia reperfusion (IR) with PBS (Hx I/R group, n=15), and 70% Hx following IR 
with ADSCs (1.0×105 cells / mouse, injected from tail vein; Hx I/R ADSC group, n=22). 
The 70% Hx was performed using the modified technique of Higgins and Anderson ［27］. 
The hepatoduodenal ligament was clamped for 15 minutes before Hx, and the ADSCs in 
a volume of 100 µl or PBS were injected just after the Hx. The mice were killed at six 
hours and 24 hours［28］after reperfusion (Fig. 1 A). We compared the mice’s serum liver 
function test results between the two groups. In addition, a lethal model was used where 
the hepatoduodenal ligament was clamped for up to 20 minutes and the mice were 
killed at 24 hours［29］after reperfusion (Fig. 1 B). We compared the survival and liver 
regeneration rates of the mice. The liver regeneration rate was defined as the ratio of 
liver weight to body weight (Lw/Bw) ［27］. The present study was conducted under the 
supervision of the Division for Animal Research Resources, Institute of Health 
Biosciences, University of Tokushima. The experiments and procedures were approved 
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by the University of Tokushima’s Animal Care and Use Committee. 
Serum liver function test 
     To evaluate liver injury, the levels of serum aspartate aminotransferase (AST), 
serum alanine aminotransferase (ALT) and total bilirubin (T-Bil) were measured using 
the Japan Society of Clinical Chemistry standardization matching method. All 
measurements were performed by Shikoku Chuken, INC. Kagawa, Japan. 
Isolation of murine hepatocytes  
     Hepatocytes were isolated from six-weeks-old female BALB/c nu-nu mice 
(Charles River™, Tokyo, Japan) using a two-step collagenase perfusion method set out 
by Seglen ［30］.and Casciano ［31］. All harvests yielded hepatocytes with viability 
exceeding 90% as determined by trypan blue dye exclusion.  
Co-culture of hepatocytes with ADSCs  
     A Transwell System (0.4 µm pore size membrane, Corning, Acton, MA) was used 
to prevent ADSCs from contacting hepatocytes. Human ADSCs (1.0 × 105) were loaded 
into the lower chamber of the well, and murine hepatocytes (1.0 × 105) were added to 
the upper chamber coated by type 1 collagen (Fig. 2). The hepatocytes were co-cultured 
with ADSCs for seven days (n=4), and the viabilities of hepatocytes were evaluated 
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over time (days 1, 3, 5 and 7). We also examined the protein levels of cytokines and 
growth factors, such as VEGF, HGF and tumor necrosis factor-α (TNF-α) in the medium. 
For the control group (n=4), hepatocytes were cultured alone without ADSCs and 
compared with co-culture groups.  
Measurement of protein levels of cytokines and growth factors  
     The protein levels of human VEGF, HGF and TNF-α in the cell culture 
supernatants were determined by ELISA, which was performed at Shikoku Chuken, 
INC. Kagawa, Japan. 
Cell viability 
     Propidium iodide (PI) and fluorescein diacetate (FDA) were used to evaluate the 
viability of hepatocytes. Hepatocytes were rinsed with PBS and stained with solution 
(10 μg/ml PI, 20 μg/ml FDA, 2% FBS, and 0.1% BSA in PBS) at room temperature for 
five minutes. The intracellular fluorescence was observed and documented with an 
inverted fluorescent microscope (Model IX70, Olympus Optical Co., Japan). The cell 
viability in each group was calculated by measuring the average green fluorescent area 
in five random low power fields.  
Administration of bevacizumab 
     In order to confirm the effect of VEGF on hepatocytes bevacizumab was used, a 
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humanized anti-VEGF monoclonal antibody. Bevacizumab was purchased from Chugai 
Pharmaceutical™, Tokyo, Japan. Bevacizumab has been reported to have cross 
reactivity with mice［32］. Bevacizumab (0.25 mg/mL) was administered into the culture 
medium［33, 34］, and the viabilities of hepatocytes were compared with and without 
bevacizumab.  
Cell culture grouping 
     Cell culturing was divided into three groups; single hepatocytes culture (Control 
group n=4), and co-culture ADSCs with hepatocytes (ADSC group n=4), and co-culture 
ADSCs with hepatocytes being administrated bevacizumab (Bev. group n=4). 
Statistical Analysis 
    All results were presented as mean ± SD. Multiple group comparisons were 
performed using one-way analyses of variance followed by the Scheffe procedure for 
comparison of means. Comparisons between the two groups were performed using the 
Mann-Whitney U-test using statistical software (JMP 8.0.1., SAS Campus Drive, Cary, 
27513 NC, USA). A p-value of less than 0.05 was considered statistically significant. 
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Results: 
Transplantation of ADSCs into mice with liver injury 
     In the Hx I/R ADSC group (n=11), serum levels of AST, ALT, and T-Bil at six 
hours after reperfusion were significantly lower than those in the Hx I/R group (n=11). 
(AST: 3,793±306 vs. 5,748±710 U/l, p=0.024, ALT: 2,443±163 vs. 3,672±353 U/l, 
p=0.017, T-Bil: 0.17±0.02 vs. 0.48±0.08 mg/dl, p<0.01) (Fig. 3). Additionally, at 
24hours after reperfusion, serum levels of AST, ALT, and T-Bil in the Hx I/R ADSC 
group (n=7) tended to be lower than those in the Hx I/R group (n=4). (AST: 3,886±364 
vs. 6,920±1978 U/l, p=0.07, ALT: 3,213±328 vs. 4,668±1679 U/l, p=0.29, T-Bil: 
0.18±0.04 vs. 0.90±0.47 mg/dl, p=0.07) (Fig. 3). In the lethal model, the liver 
regeneration rate (Lw/Bw) at 24 hours after reperfusion in the Hx I/R ADSC group 
(n=7) tended to be stimulated compared to the Hx I/R ADSC group (n=4) (2.68±0.49 vs. 
2.16±0.19, p=0.07) (Fig. 4). The survival rate at 24 hours after reperfusion in the Hx I/R 
ADSC group was 41.2% (7/17), while in the Hx I/R group it was 23.5% (4/17).  
Identification of ADSCs-secreted molecules 
     In the ADSC group, VEGF concentration levels in the culture medium were 
significantly higher than in the control group. Furthermore, VEGF levels in the ADSC 
group increased in a time-dependent manner until day 7. HGF levels were significantly 
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higher than those in the control group at day 5. On the other hand, there were no 
significant differences in TNF-α levels between the two groups (Fig. 5). 
Quality assessment of hepatocytes co-cultured with and without ADSCs 
     The cell viabilities of the ADSC group were significantly better than those of the 
control group at days 3, 5 and 7. (89.6±9.5 vs. 54.9±7.4% at day 3 p<0.05, 51.0±6.0 vs. 
26.0±7.3% at day 5 p<0.05, 25.0±7.9 vs. 7.3±5. % at day 7 p<0.05) (Fig. 6). 
The effect of VEGF signal on the quality of hepatocytes 
       After administration of bevacizumab into the culture medium, VEGF 
concentration (1,703±289 pg/ml at day7) substantially decreased (12±3 pg/ml at 
day7) in the ADSC group. However, the inhibited production of VEGF caused by the 
bevacizumab did not affect the cell viability of hepatocytes (Fig. 6). Therefore, the 
protective effects of ADSCs on hepatocytes might be provided by molecular 
mechanisms other than VEGF signaling. 
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Discussion 
     Recent studies have suggested that the therapeutic capacity possessed by ADSCs 
for liver disorders might stem from trophic effects resulting from factors such as the 
various types of cytokines and chemokines they produce ［35,36］. Herein, we 
demonstrated the following findings: (1) In vivo, ADSCs had beneficial effects for liver 
injury after subsequent Hx and I/R. (2) In vitro, ADSCs’ trophic molecules, including 
VEGF and HGF, protected hepatocytes. However, suppression of VEGF by the 
administration of bevacizumab did not affect the protective effects of ADSCs.  
     In recent years, MSCs transplantation has been widely used in animal models of 
cerebral infarction, myocardial infarction, and renal I/R injury to regenerate the 
damaged tissues. Some of these reports have demonstrated the effectiveness of MSCs 
transplantation against drug-induced liver injury ［35, 37］. However, the effects of MSCs 
on hepatic I/R injury remain uncertain. In a model of drug-induced chronic liver disease, 
it was shown that the transplanted MSCs provided antifibrotic effects. They also showed 
that these MSCs scattered mostly in the hepatic connective tissue and survived in the 
liver for four weeks after the transplantation, but did not differentiate into hepatocytes 
expressing albumin or alpha-fetoprotein［37］. This suggests that a variety of bioactive 
cytokines secreted by the transplanted MSCs, such as VEGF, HGF and FGF, might be 
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involved in restoring liver function and promoting regeneration.  
     In models of acute liver disease due to I/R injury, free radicals generated during 
the acute phase of I/R injury initiate the inflammatory cascade, giving rise to the second 
attack, which is characterized by the infiltration of activated neutrophils in the liver 
promptly after reperfusion. Activation of Kupffer cells and T lymphocytes promotes 
neutrophil recruitment, assisted by increased endothelial expression of adhesion 
molecules［38］. Therefore, it seems that the transplanted MSCs should work efficiently 
just after the reperfusion. In the present study, the administration of ADSCs ameliorated 
the increase in serum transaminase and T-Bil levels at six hours after reperfusion, which 
serves as the most sensitive marker for clinical and experimental hepatic I/R injury 
evaluation. These findings suggest that the ADSCs were viable and able to function 
shortly after the transplantation. In our lethal model, our preliminary data suggests that 
the ADSCs tended to stimulate the remnant liver regeneration at 24 hours after 
reperfusion. Kanazawa H. et al.［38］reported that MSCs stimulated liver regeneration 
after I/R injury by several cytokines secreted by the transplanted MSCs. Indeed, ADSCs 
have been reported to secrete anti-inflammatory ［39］and anti-oxidative ［40］cytokines, and 
these effects attenuate I/R liver injury and stimulate liver regeneration.  
     ADSCs have been reported to secrete various cytokines, including VEGF, HGF, 
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NGF, and FGF, being active in hepatocyte proliferation. However, these cells are also 
rich in the production of anti-inflammatory cytokines, such as IL-1Ra and IL-10, thus 
indicating a relationship between mechanisms for suppressing concentrations of 
inflamed cells and recovery from liver damage［35］. In our study, the culture medium in 
the ADSC group had a higher content of VEGF and HGF. Furthermore, the VEGF 
levels in the ADSC group elevated in a time-dependent manner. In our previous study, 
ADSCs secreted sufficient amounts of VEGF, IL-6 and IL-8 by co-culturing with 
injured porcine islets, especially in the VEGF (data not shown). Therefore, we 
speculated that the VEGF signal should have a key role in hepatocytes protection. In 
fact, Park et al. ［20］reported that the VEGF signal plays a key role in the cell protective 
effects of MSCs. They co-cultured the MSCs with mice’s islets and VEGF was detected 
at higher concentrations and demonstrated a critical correlation with islet quality. 
Furthermore, co-cultured islets demonstrated increased levels of VEGF-receptor 2, 
being a VEGF-A-induced signaling［41］, and the phosphorylation of Akt. VEGF is a 
well-known signal protein produced by cells that stimulates vasculogenesis and 
angiogenesis, and the most important member is VEGF-A［22, 23］. On the other hand, it 
was reported that VEGF might suppress the apoptosis of K562 cells through its 
influence on the bcl-X(L)/Bax expression ratio in K562 cells［24］. Kosaka N et al. 
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reported VEGF suppressed granulosa cell apoptosis by inhibiting the release of 
caspase-activated DNase (CAD) ［25］. That is to say, VEGF might not only correlate to 
vasculogenesis and angiogenesis but also have anti-apoptotic effects. In the current 
results, however, the inhibition of VEGF production by bevacizumab did not affect the 
viability of hepatocytes (Fig. 6). Therefore, the protective effects of ADSCs on 
hepatocytes might be provided by mechanisms other than VEGF signaling. In fact, HGF 
concentration of the culture medium in the ADSC group was significantly higher at 
day5. Since several cytokines, such as HGF, FGF, IGF, NGF, FGF, IL-1Ra, and IL-10 
were reported to have cytoprotective or anti-inflammatory effects on hepatocytes［35, 36］, 
it is possible that such cytokines might be key molecules in the protection of 
hepatocytes, although further studies are required. 
     In conclusion, the ADSCs ameliorated the liver injury and stimulated remnant 
liver regeneration after Hx and I/R injury in mice. Furthermore, the administration of 
ADSCs protected hepatocytes due to their trophic molecules, although such protective 
effects might be provided by mechanisms other than VEGF signaling. Therefore, an 
ADSCs-based strategy might have therapeutic potential in the prevention of liver 
failure. 
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Figure legends: 
Figure 1 
     (A) Experimental protocol. Non-lethal model. BALB/c nu-nu mice were divided  
into two groups: 70% hepatectomy (Hx) following ischemia reperfusion (Hx I/R n=15),  
70% Hx following IR with ADSC (1.0×105 cells / mouse, injected from tail vein; Hx I/R  
ADSC, n=22). ADSC was injected just after Hx. The hepatoduodenal ligament was  
clamped for 15 minutes before Hx. The mice were killed at six and 24 hours after Hx.  
     (B) Lethal model. The hepatoduodenal ligament was clamped for up to 20 
 minutes, and the mice were killed at 24 hours after reperfusion.  
Figure 2 
     A Transwell System. Human ADSCs (1.0 × 105) were loaded into the lower  
chamber of the well, and murine hepatocytes (1.0 × 105) were added to the upper  
chamber coated by type 1 collagen. 
Figure 3 
     Serum transaminase and T-Bil levels at six and 24 hours after reperfusion. ADSCs 
significantly improved serum liver function at six hours after reperfusion in Hx and I/R 
injured mice. 
Figure 4 
28 
 
     Lw / Bw at 24 hours after reperfusion. ADSCs tended to stimulate liver 
regeneration in severe Hx and I/R injured mice. 
Figure 5 
     Identification of ADSCs-secreted molecules. In the ADSC group, VEGF and 
HGF concentration in the culture medium increased more than in the control group. 
Figure 6 
     Quality assessment of hepatocytes. ADSCs improved the viabilities of  
hepatocytes on days 3, 5 and 7. The inhibited production of VEGF by bevacizumab did 
not affect the cell viability of hepatocytes.  
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